Treatment algorithm

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer

ACUTE

pregnant: susceptible to and exposed to rubella

Back
1st line – 

specialist referral

Pregnant women with known exposure to rubella who are susceptible to rubella or who have uncertain immunity (no or unknown immunization history and no previous serologic testing), whether or not they are symptomatic, should be referred to a high-risk perinatal specialist and a pediatric infectious disease specialist to evaluate the likelihood of fetal infection and risk of sequelae.

Back
Consider – 

intramuscular immune globulin

Treatment recommended for SOME patients in selected patient group

High dose polyclonal immune globulin may be of benefit for preventing clinical rubella but is not routinely recommended for this purpose because there is insufficient evidence for prevention of congenital rubella in the fetus.[45]​ This option may be considered for post-exposure prophylaxis.​

Primary options

immune globulin (human): 0.55 mL/kg intramuscularly as a single dose

nonpregnant: symptomatic rubella

Back
1st line – 

supportive care

Postnatal rubella is generally a mild, self-limited condition that requires only symptomatic therapy. No specific antiviral therapy is available. A brief course of an NSAID, if no contraindication exists, may be helpful for patients with arthritis.

back arrow

Choose a patient group to see our recommendations

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer

Use of this content is subject to our disclaimer